Amundi
LAB icon

Amundi’s Standard BioTools LAB Stock Holding History

Amundi’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,497
Closed -$15.5K – 1948
2025
Q1 		$15.5K Hold
14,497
– – ﹤0.01% 1865
2024
Q4 		$25.4K Hold
14,497
– – ﹤0.01% 1876
2024
Q3 		$26.1K Hold
14,497
– – ﹤0.01% 1895
2024
Q2 		$26.7K Buy
+14,497
New +$35.4K ﹤0.01% 1826

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Amundi's LAB Position: Q2 2025 in Review

Amundi sold out of Standard BioTools (LAB) in Q2 2025, closing a stake of 14,497 shares — an estimated $15.5K sold.

Amundi first reported a position in LAB in Q2 2024 and held it in 4 quarters. The position peaked at $26.7K in Q2 2024. 160 funds tracked by Wall St. Rank hold LAB as of Q2 2025.

  • Amundi reported no remaining Standard BioTools position as of Q2 2025 after selling out during the quarter.
  • Amundi sold 14,497 Standard BioTools shares in Q2 2025, an estimated $15.5K.
  • Amundi first reported a position in Standard BioTools in Q2 2024 and held it in 4 quarters.
  • Amundi's Standard BioTools position peaked at $26.7K in Q2 2024.
  • 160 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2025.

Based on Amundi's 13F filing for Q2 2025, filed 13 Aug 2025.